An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein-Barr Virus-associated Diseases
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
Sponsor: Atara Biotherapeutics, Inc
Enrolling: Male and Female Patients
IRB Number: AAAT5002
U.S. Govt. ID: NCT04554914
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of the study is to: 1. Assess the safety of tabelecleucel. This will include looking at what adverse events (sometimes called side effects) occur and how often they occur. 2. Assess the effects of tabelecleucel on your Epstein-barr Virus (EBV) disease.
This study is closed
Investigator
Ran Reshef, MD
Do You Qualify?
Are you age 18 or older? Yes No
Have you been diagnosed with Epstein-barr virus? Yes No
Are you able to provide written informed consent? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE